Cipla Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 16, 2025, Speech by Chairman, and presentation by MD&GCEO
CIPLA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cipla held its 89th AGM on July 16, 2025, via video conferencing, marking the company's 90th year in August 2025. Management presented strong FY25 results: revenue of INR 27,548 Cr (8% YoY growth), EBITDA of INR 11,615 Cr (7% YoY) with highest-ever EBITDA margin, and PAT growth of 12% YoY. Segment-wise, One India grew 15% to INR 7,128 Cr, One Africa rose 14% to INR 5,273 Cr, and North America margins expanded to 25.9% (up 139 bps). Key respiratory drug Foracort crossed INR 900 Cr in revenue, and the company holds a net cash position of over INR 10,000 Cr with RoIC of 33.1%. All 5 USFDA facility audits in FY25 received 'VAI' classification. All 6 resolutions, including dividend declaration and re-appointment of MD Umang Vohra, were passed by shareholders.
This is a routine AGM compliance filing — no negative surprises. Shareholders can expect the declared dividend (amount yet to be announced) as the key actionable outcome, alongside continued confidence in the company's growth trajectory and strong balance sheet.